Figure 4
From: AXL inhibition improves BRAF-targeted treatment in melanoma
Melanoma cells show response to BRAFi and AXLi. Expression levels of proteins measured by FLOW (recording ≥ 2.5 × 104 cells) in the differently treated Melmet 1 and A375 cells (2 µM BRAFi, 2 µM AXLi or a combination of both, DMSO for control) for 48 h and presented as relative to respective non-treated controls set to 100%. Average of signal median ± SEM, n = 3. *p ≤ 0.05; **p ≤ 0.01; and ***p ≤ 0.001.
